Nouscom to Present Full Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022

/PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced...

Related Keywords

Italy ,Ankara ,Turkey ,United States ,Rome ,Lazio ,Switzerland ,Chicago ,Illinois ,American ,Marwan Fakih ,Eleanor Perkin ,Rick Davis ,Sylvie Berrebi ,Linkedin ,American Society Of Clinical Oncology ,Clinical Oncology ,Microsatellite Instable High ,Presentation Details ,Medical Oncology Specialist ,Duarte California ,Great Ape Adenoviral ,Modified Vaccinia Ankara ,Nouscom ,